

Revolutionizing Nerve Repair One Gap at a Time!™




#### Introduction

- Safe and effective product
- Protected intellectual property
- Defined regulatory pathway



#### Clinical Need







#### Clinical Need

- Complications from surgeries
- Car/machinery accidents
- Tumor removal
- Gunshot wounds
- Slips/falls









# The Challenge













#### Our Solution: AxoMax® Nerve Guide



- AxoMax® nerve guide is a biodegradable tube comprised of FDAapproved materials
- Spent 15 years optimizing properties
- In a large animal model, AxoMax® nerve guide repaired a 2 inch median nerve defect
- R & D is complete



# Competition



Company	Repair nerve gaps > 1"
AxoMax Technologies	<b>✓</b>
Stryker	X
Integra	X
Baxter	X
Polyganics	X
Medovent	X

**AxoMax** Nerve Guide will be the first and only tube on the market with 510(k) clearance that works for gaps greater than 1"!

# **Efficacy and Safety**





AxoMax Nerve Guide (~80%)

Empty Tube (~35%)






Fadia et al, Science Translational Medicine, 2020, 12(527) 1-13.



# Intellectual Property and Product Pipeline

- Slow release of proteins that promotes nerve growth
- AxoMax Technologies, Inc. has licensed technology from University of Pittsburgh
  - 2 Issued Patents: 9498221, 9750851
  - 3 Filed Patents

#### AxoMax® Nerve Guide



AxoDip<sup>TM</sup>





### Funding to Date: ~\$3 Million

- Raised through:
  - Grants (non-dilutive funding)
    - Department of Defense, National Institutes of Health and National Science Foundation
  - Pre-seed round (Friends and Family)



## Financing to Bring Product to Market

- Seed: \$1M
  - Obtain Investigational Device Exemption (IDE) approval from the FDA
  - Complete ISO testing (Includes biocompatibility and shelf life testing)
- Series A: \$6M
  - Conduct first-in-human clinical trial
  - Obtain 510(k) clearance from the FDA


#### **Product Roadmap**







#### **Total Market Size: \$2.7B**



#### Team





Kacey Marra, PhD Founder and CEO Professor, University of Pittsburgh



Ben Schilling, MS **Chief Technology Officer (CTO)** Bioengineer; Founder of Benchtop **Bioreactors** 


#### **Advisory Board**



Steve Winowich, BS President, ProCirca

Neurologist,

Mayo Clinic



Arta Kelmendi-Doko, MD, PhD Bioengineer, 3M M\*Modal



Kia Washington, MD Plastic Surgeon, University of Colorado

Strategic Business Advisor



Craig Markovitz, MBA Founder/CEO of Blue Belt Technologies, Inc. COO of HealthPointCapital





#### **Development Timeline**

Leveraging 15 years of academic research



Funding: Non-dilutive Pre-Seed Seed Series A \$3M \$125K \$1M \$6M



### Summary

- Safe and effective product
- Yes! Small & large animal studies
- Protected intellectual property
- Yes! Patented & licensed our technology
- Defined regulatory pathway
- Yes! Class II medical device



# Thank you!

www.axomax.com

Revolutionizing Nerve Repair One Gap at a Time.™